← Leaderboards
William Gerald Teague
University Of Virginia
$5,830,751
Attributed
$11,652,267
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,652,267 · 7
By mechanism
U10$4,735,118 · 2
UG1$2,436,127 · 1
R01$2,083,062 · 1
U01$1,768,074 · 1
R21$444,125 · 1
M01$185,761 · 1
Top collaborators
- Serpil C. Erzurum12 shared
- Benjamin M Gaston12 shared
- Jie Sun3 shared
- Larry C Borish2 shared
- Stephen P Peters2 shared
Most similar at University Of Virginia
Same institution · by research overlap
- Yun Michael Shim$6,424,060
- Kun Qing$2,843,545
- Imre Noth$12,167,659
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseAsthmaChildProgramsResearch PersonnelRespiratory PhysiologyMorbidity - Disease RateAdrenal Cortex HormonesEosinophilBiological MarkersClinical TrialsAdultUnited States National Institutes Of HealthRandomizedSiteCostOxidative StressNational Heart, Lung, And Blood InstituteSerumBaseAccountingAntioxidantsMale AdolescentsUrine
Grant awards (25)
Determinants of Convalescent and Vaccine-induced Mucosal Specific Immunity to SARS-CoV-2 and Variants of Concern in Children with Asthma$678,376
R01 · FY2025 · AI · contact PI
Determinants of Convalescent and Vaccine-induced Mucosal Specific Immunity to SARS-CoV-2 and Variants of Concern in Children with Asthma$697,498
R01 · FY2024 · AI · contact PI
Determinants of Convalescent and Vaccine-induced Mucosal Specific Immunity to SARS-CoV-2 and Variants of Concern in Children with Asthma$707,188
R01 · FY2023 · AI · contact PI
Clinical Centers for the NHLBI's Precision Interventions for Severe and/or Exacerbation Prone Asthma (PrecISE) Network (UG1)$384,857
UG1 · FY2022 · HL
Clinical Centers for the NHLBI's Precision Interventions for Severe and/or Exacerbation Prone Asthma (PrecISE) Network (UG1)$424,886
UG1 · FY2021 · HL
Lung rhinovirus (RV) infection identifies pre-school children with type 2 inflammation at risk for the development of asthma$242,250
R21 · FY2021 · AI
Clinical Centers for the NHLBI's Precision Interventions for Severe and/or Exacerbation Prone Asthma (PrecISE) Network (UG1)$424,886
UG1 · FY2020 · HL
Lung rhinovirus (RV) infection identifies pre-school children with type 2 inflammation at risk for the development of asthma$201,875
R21 · FY2020 · AI
Clinical Centers for the NHLBI's Precision Interventions for Severe and/or Exacerbation Prone Asthma (PrecISE) Network (UG1)$424,886
UG1 · FY2019 · HL
Clinical Centers for the NHLBI's Precision Interventions for Severe and/or Exacerbation Prone Asthma (PrecISE) Network (UG1)$426,276
UG1 · FY2018 · HL
Clinical Centers for the NHLBI's Precision Interventions for Severe and/or Exacerbation Prone Asthma (PrecISE) Network (UG1)$350,336
UG1 · FY2017 · HL
Airway redox biochemistry as a deteriminant of asthma phenotype during adolescen*$704,644
U10 · FY2016 · HL
Airway redox biochemistry as a deteriminant of asthma phenotype during adolescen*$696,313
U10 · FY2015 · HL
Airway redox biochemistry as a deteriminant of asthma phenotype during adolescen*$713,516
U10 · FY2014 · HL
Airway redox biochemistry as a deteriminant of asthma phenotype during adolescen*$84,615
U10 · FY2014 · HL
Airway redox biochemistry as a deteriminant of asthma phenotype during adolescen*$680,555
U10 · FY2013 · HL
Airway redox biochemistry as a deteriminant of asthma phenotype during adolescen*$518,031
U10 · FY2012 · HL
Atlantic Coast Consortium for Asthma (ACC-A) AsthmaNet Clinical Site$840,094
U10 · FY2010 · HL
Study of Acid Reflux Therapy for Children with Asthma$296,125
U01 · FY2010 · HL · contact PI
CLINICAL TRIAL: PHASE II STUDY OF UNADJUVANTED NOVARTIS H1N1 INFLUENZA VACCINE I$185,761
M01 · FY2010 · RR · contact PI
Atlantic Coast Consortium for Asthma (ACC-A) AsthmaNet Clinical Site$497,350
U10 · FY2009 · HL
Study of Acid Reflux Therapy for Children with Asthma$402,868
U01 · FY2009 · HL · contact PI
Study of Acid Reflux Therapy for Children with Asthma$383,681
U01 · FY2008 · HL · contact PI
Study of Acid Reflux Therapy for Children with Asthma$392,622
U01 · FY2007 · HL · contact PI
Study of Acid Reflux Therapy for Children with Asthma$292,778
U01 · FY2006 · HL · contact PI